Review of tenofovir use in HIV-infected children
© 2015 Wolters Kluwer Health, Inc. Tenofovir disoproxil fumarate (TDF) is approved by the Food and Drug Administration for use in children ages 2 years and older and is recommended by the World Health Organization for use as a preferred first-line nucleotide reverse transcriptase inhibitor in adults...
Saved in:
Main Authors: | Linda Aurpibul, Thanyawee Puthanakit |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84937632315&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/54788 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Review of tenofovir use in HIV-infected children
by: Linda Aurpibul, et al.
Published: (2018) -
Second-line Antiretroviral therapy for HIV-infected children in resource limited settings
by: Linda Aurpibul, et al.
Published: (2018) -
Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen
by: Linda Aurpibul, et al.
Published: (2019) -
Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents
by: Tavitiya Sudjaritruk, et al.
Published: (2018) -
Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
by: Linda Aurpibul, et al.
Published: (2018)